RARE
Ultragenyx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RARE
Ultragenyx Pharmaceutical Inc.
A biopharmaceutical company that developing novel products for serious debilitating genetic diseases
Biological Technology
04/22/2010
01/31/2014
NASDAQ Stock Exchange
1,294
12-31
Common stock
60 Leveroni Court
, Novato
, California 94949
--
Ultragenyx Pharmaceutical Inc., established on April 22, 2010, is a developing-stage biotechnology company, which was subsequently re-incorporated in Delaware in June 2011. The company focuses on the identification, acquisition, development and commercialization of novel products for the treatment of rare and very rare diseases, with the original goal of the products for the treatment of severe, debilitating metabolic genetic diseases. The company's sustained-release sialic acid is currently in the second phase of clinical trials for the treatment of patients with hereditary inclusion body myopathy, a progressive muscle-wasting disease.
Earnings Call
Q1/2025
Estimate EPS-1.64
Actual EPS-1.57
Estimate Revenue144.46M
Actual Revenue139.29M
Ultragenyx's Q1 2025 Earnings Call: Navigating Contradictions in Trial Success, Therapy Duration, and Data Timelines
May 07,2025 07:26
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-1.33
Actual EPS-1.17
Estimate Revenue161.37M
Actual Revenue166.50M
Ultragenyx's Q2 2025 Earnings Call: Dissecting Contradictions on Setrusumab Efficacy, FDA Interactions, and Resubmission Strategy
Aug 06,2025 12:50
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
RARE has released its 2025 Q3 earnings. EPS was reported at -1.81, versus the expected -1.21, missing expectations. The chart below visualizes how RARE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RARE has released its 2025 Q3 earnings report, with revenue of 159.93M, reflecting a YoY change of 14.65%, and net profit of -180.41M, showing a YoY change of -35.12%. The Sankey diagram below clearly presents RARE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
